Biopharma merger and acquisition value for the fourth quarter of 2024 reached $9.4bn from 34 transactions, 15 of which had disclosed values. At the top was H. Lundbeck’s $2.6bn purchase of publicly traded US biotech Longboard Pharmaceuticals. This deal and four other M&A transactions hit or exceeded the billion-dollar mark during Q4 (see Exhibit 1).
Dealmaking Quarterly Statistics, Q4 2024
A Look At M&A And Alliance Activity Across The Biopharma, Medical Device And In Vitro Diagnostics Industries, October - December 2024
During Q4, biopharma merger and acquisition deal value reached $9.4bn and drew in $72.8bn in potential deal value from alliances. Device company M&A values reached $395m, while in vitro diagnostics and research tools players’ M&A activity totaled $604m.
More from Deal-Making
• By
Laura Lane, European head of Lilly Ventures, talked to In Vivo at the recent Bio-Europe meeting in a fireside chat about how strategic investments are shaping the future of biotech, Lilly's approach to early-stage innovation, and the evolving European investment landscape.
• By
TechBio stands at a critical inflection point, where computational innovation meets the reality of biopharma. Industry leaders have begun to cut through the hype and identify where sustainable value truly lies in this rapidly evolving landscape.
• By
Three $1bn+ alliances were penned in February, and one exceeded $2bn.
• By
An interactive look at pharma, medtech and diagnostics deals made during February 2025. Data courtesy of Biomedtracker.
More from Market Intelligence
• By
Rentschler Biopharma CEO Benedikt von Braunmühl tells In Vivo about the CDMO's strategic decision to exit the cell and gene therapy manufacturing space.
• By
Twenty executives in the biopharma industry outline their expectations for key trends and developments this year. A selection of commentary from a broad industry survey by Scrip.
• By
Swiss firm Molecular Partners and French national offshoot Orano Med have partnered to develop a potent new class of radiopharmaceuticals.